---
title: "While institutions invested in Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) benefited from last week's 12% gain, individual investors stood to gain the most"
description: "Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) saw a 12% stock price increase last week, benefiting both individual and institutional investors. Individual investors hold 40% of the company, giving them s"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/258882326.md"
published_at: "2025-09-25T12:15:39.000Z"
---

# While institutions invested in Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) benefited from last week's 12% gain, individual investors stood to gain the most

> Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) saw a 12% stock price increase last week, benefiting both individual and institutional investors. Individual investors hold 40% of the company, giving them significant influence over management and strategy, while institutions own 37%. The top 12 shareholders collectively own 51%, indicating no single majority owner. Hedge funds own 9.5%, and insiders hold shares worth $18 million. The general public's 40% ownership allows for some sway in company policies, while private equity firms hold a 9.6% stake, suggesting potential influence in key decisions.

### Key Insights

-   The considerable ownership by individual investors in Corvus Pharmaceuticals indicates that they collectively have a greater say in management and business strategy
-   51% of the business is held by the top 12 shareholders
-   Institutional ownership in Corvus Pharmaceuticals is 37%

Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit.

To get a sense of who is truly in control of Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), it is important to understand the ownership structure of the business. And the group that holds the biggest piece of the pie are individual investors with 40% ownership. In other words, the group stands to gain the most (or lose the most) from their investment into the company.

Following a 12% increase in the stock price last week, individual investors profited the most, but institutions who own 37% stock also stood to gain from the increase.

Let's delve deeper into each type of owner of Corvus Pharmaceuticals, beginning with the chart below.

View our latest analysis for Corvus Pharmaceuticals

## What Does The Institutional Ownership Tell Us About Corvus Pharmaceuticals?

Institutional investors commonly compare their own returns to the returns of a commonly followed index. So they generally do consider buying larger companies that are included in the relevant benchmark index.

We can see that Corvus Pharmaceuticals does have institutional investors; and they hold a good portion of the company's stock. This implies the analysts working for those institutions have looked at the stock and they like it. But just like anyone else, they could be wrong. It is not uncommon to see a big share price drop if two large institutional investors try to sell out of a stock at the same time. So it is worth checking the past earnings trajectory of Corvus Pharmaceuticals, (below). Of course, keep in mind that there are other factors to consider, too.

Our data indicates that hedge funds own 9.5% of Corvus Pharmaceuticals. That worth noting, since hedge funds are often quite active investors, who may try to influence management. Many want to see value creation (and a higher share price) in the short term or medium term. Looking at our data, we can see that the largest shareholder is OrbiMed Advisors LLC with 9.6% of shares outstanding. For context, the second largest shareholder holds about 9.5% of the shares outstanding, followed by an ownership of 5.7% by the third-largest shareholder. Furthermore, CEO Richard Miller is the owner of 3.1% of the company's shares.

A closer look at our ownership figures suggests that the top 12 shareholders have a combined ownership of 51% implying that no single shareholder has a majority.

While studying institutional ownership for a company can add value to your research, it is also a good practice to research analyst recommendations to get a deeper understand of a stock's expected performance. There are a reasonable number of analysts covering the stock, so it might be useful to find out their aggregate view on the future.

## Insider Ownership Of Corvus Pharmaceuticals

While the precise definition of an insider can be subjective, almost everyone considers board members to be insiders. The company management answer to the board and the latter should represent the interests of shareholders. Notably, sometimes top-level managers are on the board themselves.

Most consider insider ownership a positive because it can indicate the board is well aligned with other shareholders. However, on some occasions too much power is concentrated within this group.

We can report that insiders do own shares in Corvus Pharmaceuticals, Inc.. As individuals, the insiders collectively own US$18m worth of the US$456m company. It is good to see some investment by insiders, but it might be worth checking if those insiders have been buying.

## General Public Ownership

With a 40% ownership, the general public, mostly comprising of individual investors, have some degree of sway over Corvus Pharmaceuticals. While this size of ownership may not be enough to sway a policy decision in their favour, they can still make a collective impact on company policies.

## Private Equity Ownership

Private equity firms hold a 9.6% stake in Corvus Pharmaceuticals. This suggests they can be influential in key policy decisions. Sometimes we see private equity stick around for the long term, but generally speaking they have a shorter investment horizon and -- as the name suggests -- don't invest in public companies much. After some time they may look to sell and redeploy capital elsewhere.

## Next Steps:

It's always worth thinking about the different groups who own shares in a company. But to understand Corvus Pharmaceuticals better, we need to consider many other factors. Take risks for example - Corvus Pharmaceuticals has **3 warning signs** (and 1 which is significant) we think you should know about.

But ultimately **it is the future**, not the past, that will determine how well the owners of this business will do. Therefore we think it advisable to take a look at this free report showing whether analysts are predicting a brighter future.

NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.

### Related Stocks

- [CRVS.US - Corvus Pharma](https://longbridge.com/en/quote/CRVS.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Corvus Pharmaceuticals (CRVS) Expected to Announce Earnings on Tuesday | Corvus Pharmaceuticals (NASDAQ:CRVS) is set to announce its Q3 2025 earnings on November 4, with analysts predicting a l | [Link](https://longbridge.com/en/news/263733861.md) |
| Corvus Pharmaceuticals Reports Positive Q3 Earnings Call | Corvus Pharmaceuticals reported positive Q3 earnings, highlighting a significant reduction in net loss to $10.2 million  | [Link](https://longbridge.com/en/news/264535679.md) |
| IHI, IHE, ARKG: Specialty Healthcare ETFs Can Help Boost a Portfolio | Specialty healthcare ETFs can enhance investment portfolios by focusing on distinct sectors like pharmaceuticals, medica | [Link](https://longbridge.com/en/news/276080275.md) |
| Zydus: From Generics to Innovation Powerhouse | Zydus Lifesciences has shifted from a generics manufacturer to an innovation-driven pharmaceutical company, focusing on  | [Link](https://longbridge.com/en/news/276109706.md) |
| A Look Into Novartis Inc's Price Over Earnings | Novartis Inc. (NYSE:NVS) stock is currently trading at $166.81, reflecting a 1.80% increase. Over the past month, the st | [Link](https://longbridge.com/en/news/276149996.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.
